Rule 4.2A

Appendix 4EPreliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited				
ABN or equivalent company reference	Financial year ended ('current period')	Financial year ended ('previous period')		
25 006 194 752	30 June 2007	30 June 2006		

2. Results for announcement to the market

ASX Listing Rules Ref		2007 A\$'000
2.1	Revenue from continuous operations	13,035
	% change up/(down) of revenue from ordinary activities from the previous corresponding period.	Up 11.9%
2.2	Profit/(Loss) after tax attributable to members	7,052
	% change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period	Up 15.3%
2.3	Net Profit/(Loss) for the period attributable to members	7,052
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 15.3%

2.4	Dividends (distributions)	Amount per security	Franked amount per security
	Franked dividend amount per security		
	Final Dividend	3.00¢	3.00¢
	Special Final Dividend	1.00¢	1.00¢
	Interim dividend	2.50¢	2.50¢
	Special Interim Dividend	0.50¢	0.50¢
2.5	Record date for Final & Special dividends	20 September, 2007	
	Payment date for Final & Special dividends	4 October, 2007	

2.6 Operating Results for the Period

Pro Medicus reported an after tax profit of \$7,052 million making this the most profitable year in Pro Medicus history. Revenue also rose to a record \$13,035 million an increase of 11.9% on the previous year.

The company's Australian operations performed well over the past year with revenue increasing by approximately 3.4% from 9.1M to 9.4M. Promedicus.net, the company's e-health offering, continued its growth in both the number of doctors registered as well as transaction volumes with the network carrying 3.1 million transactions for the year, a 7.2% increase on the previous year.

The number of doctors registered to use promedicus.net increased from 22,000 doctors to 25,300 an increase of 15% compared to the same time last year, and the company intends to leverage its relationship with them to cross-sell its other products and services.

Building on the success of the first digital imaging installation at Lake Imaging, the company has now installed the technology at an increasing number of sites, covering private, large corporate and public radiology providers. Increased levels of market interest reinforce the company's confidence that the efficiency and clinical benefits the technology offers will inevitably drive the radiology industry towards a fully digital environment.

The past year has also seen the company continue to make significant inroads into overseas markets particularly the US and Canada with revenue from overseas operations increasing from \$2.308 million to 3.092 million a 33.96% increase.

The North American market provided approximately 24% of the total revenue and Pro Medicus aims to continue to expand within this lucrative market by leveraging Agfa's substantial presence in the US and by extending its product offering.

Canada has also continued to provide ongoing opportunity for the company providing approximately 10.4% of the total revenue.

Throughout the year, the company continued its focus on higher margin software sales, e-health and services. Net margin as defined by profit before tax to revenue from operating activities increased from 75.8% in 2006 to 77.6% in 2007.

The Company is pleased to report a dividend return to shareholders of a total of 7.0 cents per share which is an increase of 1.5 cents over the previous period and represents the largest dividend payout in the company's history. This is made up of a final dividend of 3.00 cents plus a special dividend of 1.00 cent per share plus the interim dividend of 2.50 cents plus a special interim of 0.5 cents.

The directors are confident that the holdings of reserve cash after paying out both the second half and special dividends is sufficient to safeguard the development and expansion needs of the company as the business looks to increase its penetration of existing markets and new product development.

3.	Income Statement			
	Please refer to the Income Statement in the attached Finance	ial Statements.		
4.	Balance Sheet			
	Please refer to the Balance Sheet in the attached Financial S	Statements.		
5.	Cash Flow Statement			
	Please refer to the Cash Flow Statement in the attached Final	ancial Statement	S.	
6.	Details of Dividends			
		2007 \$'000	2006 \$'000	
	Final Dividend	Ψοσο	φοσσ	
	A Final Dividend of 3.00 cents (2006: 2.00) per share fully franked will be paid on 4 October 2007.	\$3000.6	\$2000	
	A Special Dividend of 1.00 cents (2006: 1.00) per share fully franked will be paid on 4 October 2007.	\$1000.2	\$1000	
	Current Year Interim An interim dividend of 2.50 cents (2006: 2.00) per share	\$2500.5	\$2000	
	fully franked was paid on 4 April 2007.	Ψ2300.3	Ψ2000	
	A Special Dividend of 0.50 cents (2006: 0.5) per share fully franked was paid on 4 April 2007.	\$500.1	\$500	
	No foreign sourced dividend or distribution is included in eith dividends.	er the interim or	final	
7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.			
8.	Statement of Retained Earnings			
	Please refer to Statement of Changes in equity in the attached	ed Financial Stat	ements.	
9.	Net Tangible Assets per security	2007	2006	
	Net Tangible Assets per security	0.12	\$0.12	
10.	Details of entities over which control has been gained or lost during the period			
	There are no entities over which control has been gained or	lost during the pe	eriod.	
11.	Associates and joint venture entities			
	There are no associates or relevant joint ventures.			
12.	Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.			
	Please refer to section 2.6.			
13.	Foreign Entity accounting standards			
	Not applicable.			

14.	Commentary on results for the period.				
	The earnings per security and the nature of any dilution aspects.				
	Please refer to Note 6 of the attached Financial Statements.				
	Returns to shareholders including distributions and buy backs.				
	Please refer to Note 7 of the attached Financial Statements.				
	Significant features of operating performance. Please refer to section 2.6.				
	10000 10101 10 00011011 2101				
	The results of segments that are significant to an understanding of the business. Please refer to Note 3 of the attached Financial Statements.				
	Flease relei to note 3 of the attached Financial Statements.				
	Discussion of trends in performance.				
	Please refer to section 2.6.				
	- 19495 1919 19 9991911 <u>- 1</u> 91				
15.	Audit Statement				
10.					
	This report is based on accounts to which one of the following applies.				
	(Tick one)				
	☐ The [†] accounts have been ☐ The [†] accounts have been subject to				
	audited. review.				
	The ⁺ accounts are in the The ⁺ accounts have not yet been				
	process of being audited or audited or reviewed.				
	subject to review.				

Sign here: Date: 28 August 2007

Print name: Sean Collins

Company Secretary